Scarica l'app Stockscreener
1.05
4.55%
-0.05
Dopo l'orario di chiusura:
1.07
0.02
+1.90%
Precedente Chiudi:
$1.10
Aprire:
$1.1
Volume 24 ore:
1.53M
Relative Volume:
1.36
Capitalizzazione di mercato:
$140.65M
Reddito:
$4.35M
Utile/perdita netta:
$-45.53M
Rapporto P/E:
-0.9722
EPS:
-1.08
Flusso di cassa netto:
$-44.79M
1 W Prestazione:
-9.48%
1M Prestazione:
-15.66%
6M Prestazione:
+32.24%
1 anno Prestazione:
+34.62%
Intervallo 1D:
$1.04
$1.10
Intervallo di 1 settimana:
$1.04
$1.2094
Portata 52W:
$0.7201
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Nome
Lucid Diagnostics Inc
Settore
Industria
Telefono
212 949 4319
Indirizzo
360 MADISON AVENUE, NEW YORK
Confronta LUCD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.05 | 140.65M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
134.11 | 233.36B | 42.34B | 13.50B | 6.66B | 7.71 |
|
BSX
Boston Scientific Corp
|
103.63 | 147.06B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
391.81 | 145.64B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
88.28 | 112.76B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
77.02 | 44.46B | 5.54B | 4.18B | 623.10M | 7.00 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Iniziato | BTIG Research | Buy |
| 2021-11-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Needham | Buy |
Lucid Diagnostics Inc Borsa (LUCD) Ultime notizie
Lucid Diagnostics Holds Annual Stockholders Meeting - TipRanks
Leading California Hospital Network Launches Revolutionary 3-Minute Cancer Detection Test from Lucid Diagnostics - Stock Titan
119,887 Shares in Lucid Diagnostics Inc. (NASDAQ:LUCD) Acquired by Citadel Advisors LLC - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price - Defense World
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 By Investing.com - Investing.com South Africa
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Maintained at Buy by Ascendiant Capital | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Target Price Increased by Ascendiant | - GuruFocus
Lucid Diagnostics Files For Offering Of 36 Million Shares Of Common Stock - MarketScreener
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
Lucid Diagnostics Enters $25M Sales Agreement - TipRanks
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com South Africa
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com Australia
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Indexes | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Joins Russell 2000 and Russell 3000 Ind - GuruFocus
Lucid Diagnostics Inc. (NASDAQ:LUCD) Receives $3.50 Consensus Price Target from Brokerages - Defense World
Certain Options of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Certain Common Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - marketscreener.com
Insider Buying: Dennis Matheis Acquires 350,000 Shares of Lucid Diagnostics Inc (LUCD) - GuruFocus
Certain Series B-1 Convertible Preferred Stock of Lucid Diagnostics Inc. are subject to a Lock-Up Agreement Ending on 25-MAY-2025. - MarketScreener
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | - GuruFocus
Lucid Diagnostics (LUCD) Director Acquires Significant Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics Joins Elite Russell Indexes, Opens Door to $10.6T Investment Pool - Stock Titan
Lucid Diagnostics Files Shelf Registration for Secondary Sale of 37 Million Shares by Convertible Note Holders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LU - GuruFocus
Lucid Diagnostics Files Prospectus For Potential Offer, Sale From Time To Time Of Up To 37 Million Shares Of Common Stock By Selling Stockholders - marketscreener.com
Lucid Diagnostics (LUCD) Files to Sell 36.98 Million Shares | LUCD Stock News - GuruFocus
Lucid Diagnostics’ SWOT analysis: stock faces reimbursement hurdles amid market potential - Investing.com Nigeria
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight - Investing.com Australia
Cantor Fitzgerald maintains Lucid Diagnostics stock Overweight By Investing.com - Investing.com India
Lucid Diagnostics’ (LUCD) Buy Rating Reiterated at Needham & Company LLC - Defense World
Cantor Fitzgerald Reiterates “Overweight” Rating for Lucid Diagnostics (NASDAQ:LUCD) - Defense World
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzg - GuruFocus
Lucid Diagnostics signals expanded market reach and $41M pro forma cash following commercial and clinical advances - MSN
Analysts Offer Insights on Healthcare Companies: Nuvation Bio (NUVB), Lucid Diagnostics (LUCD) and Arcellx Inc (ACLX) - The Globe and Mail
Lucid Diagnostics Reports Increased Losses Amid Revenue Decline - TipRanks
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Lags Revenue Estimates - MSN
Cantor maintains Lucid Diagnostics stock with $2 target after Q1 results - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Rating Reiterated by Cantor Fitzgerald | LUCD Stock News - GuruFocus
Transcript : PAVmed Inc., Q1 2025 Earnings Call, May 15, 2025 - marketscreener.com
PAVmed Inc Q1 2025 Earnings: Revenue Surges to $0.8 Million, Bea - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 F - GuruFocus
PAVmed Provides Business Update and Reports First Quarter 2025 Financial Results | PAVM Stock News - GuruFocus
Lucid Diagnostics Inc Azioni (LUCD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Lucid Diagnostics Inc Azioni (LUCD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Matheis Dennis | Director |
May 21 '25 |
Buy |
1.32 |
129,684 |
171,520 |
316,782 |
| Matheis Dennis | Director |
May 22 '25 |
Buy |
1.32 |
33,218 |
43,795 |
350,000 |
0.54%
1.82%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):